By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Drugs and Therapies have been presented. According to news reporting from Guangdong, People's Republic of China, by NewsRx journalists, research stated, "Accumulative evidence has suggested B-cell-mediated alloimmune response plays an important role in kidney transplantation. Monitoring the dynamics of B-cell subsets could enhance understanding of B-cell immunology in clinical transplantation, and may facilitate optimization of current immunosuppressive regimens."
The news correspondents obtained a quote from the research from Sun Yat Sen University, "Between June 2011 and June 2012, 16 de novo living related kidney transplant recipients were enrolled in this study. All patients were given basiliximab as induction therapy. The maintenance therapy consisted of tacrolimus, mycophenolate mofetil (MMF), and steroids. Phenotype of B-cell subsets in peripheral blood was examined at day 0, day 1, day 3, day 7, day 14, month 1, month 3, and month 6. CD19(+) B cells in peripheral lymphocytes significantly increased by 1.8-2.1 times within 1 month after transplantation, and recovered to the baseline level at month 3. Notably in B cells, CD5(+)CD19(+)B cells dramatically decreased by 45% at month 6. CD19(+)CD27(+) memory B cells increased by 127% at month 6. B-cell activating factor receptor (BAFF-R) expression on the B-cell population was maintained at a high level of 91.7%-97.9%. Within 7 days after transplantation, Bm1 (IgD(+)CD38(-)) did not change apparently, Bm2 (IgD(+)CD38(int)) significantly increased, whereas Bm2' (IgD(+)CD38(high), germinal center founder cells), Bm3+Bm4 (IgD(-)CD38(high), germinal center B cells), early Bm5 (IgD(-)CD38(int)), and late Bm5 (IgD(-)CD38(-)) significantly decreased. After day 7, Bm1 stayed stable, Bm2 decreased to the baseline level (day 0), and Bm2' and Bm3+Bm4 kept decreasing, whereas early Bm5 and late Bm5 increased to baseline level. At month 6, Bm1 significantly increased, Bm2 was maintained at the baseline level, Bm2' constantly decreased to the lowest, and Bm3(+)Bm4 was slightly lower than the baseline, whereas early and late Bm5 increased to the baseline level. The proportion of B cells in peripheral lymphocytes significantly increased at the early stage, whereas CD5(+)CD19(+)B cells consistently decreased after transplantation."
According to the news reporters, the research concluded: "Mature circulating B-cell subsets dynamically changed, especially at the early stage after transplantation, which might be attributed to the induction therapy."
For more information on this research see: Dynamic Analysis of B-Cell Subsets in De Novo Living Related Kidney Transplantation With Induction Therapy of Basiliximab. Transplantation Proceedings, 2014;46(2):363-367. Transplantation Proceedings can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Transplantation Proceedings - www.elsevier.com/wps/product/cws_home/600114)
Our news journalists report that additional information may be obtained by contacting L. Longshan, Sun Yat Sen UniversityAffiliated Hosp 1, Organ Transplant Center, Guangzhou 510080, Guangdong, People's Republic of China. Additional authors for this research include L. Dongwei, F. Qian, L. Jun, D. Suxiong, Z. Yitao, X. Yunyi, H. Huiting, C. Lizhong, F. Jiguang and W. Changxi (see also Drugs and Therapies).
Keywords for this news article include: Asia, Pharmaceuticals, Guangdong, Basiliximab, Blood Cells, Lymphocytes, Organ Transplant, Kidney Transplant, Immunologic Agents, Drugs and Therapies, Monoclonal Antibodies, Mononuclear Leukocytes, Hemic and Immune Systems, Immunosuppressive Agents, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC